Casdin Capital’s Maze Therapeutics MAZE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$22.9M Hold
843,857
– – 1% 20
2026
Q2
$25.2M Buy
843,857
+85,000
+11% +$2.23M 1.26% 16
2026
Q1
$22.7M Hold
758,857
– – 1.72% 14
2025
Q4
$31.4M Hold
758,857
– – 1.95% 11
2025
Q3
$19.7M Hold
758,857
– – 1.64% 13
2025
Q2
$9.31M Sell
758,857
-187,500
-20% -$1.95M 0.85% 17
2025
Q1
$10.4M Buy
+946,357
New +$11.4M 0.85% 21

Other funds holding MAZE

Casdin Capital's MAZE Position: Q3 2026 in Review

Casdin Capital held its Maze Therapeutics (MAZE) position steady in Q3 2026 at 843,857 shares worth $22.9M. The position accounts for 1% of the portfolio, ranked #20.

Casdin Capital first reported a position in MAZE in Q1 2025 and has held it in 7 quarters since. The position peaked at $31.4M in Q4 2025. 158 funds tracked by Wall St. Rank hold MAZE as of Q3 2026.

  • Casdin Capital held 843,857 shares of Maze Therapeutics worth $22.9M as of Q3 2026.
  • Casdin Capital left its Maze Therapeutics share count unchanged in Q3 2026.
  • Maze Therapeutics made up 1% of Casdin Capital's portfolio in Q3 2026, its #20 holding.
  • Casdin Capital first reported a position in Maze Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • Casdin Capital's Maze Therapeutics position peaked at $31.4M in Q4 2025.
  • 158 funds tracked by Wall St. Rank held Maze Therapeutics as of Q3 2026.

Based on Casdin Capital's 13F filing for Q3 2026, filed 16 Nov 2026.